HomeNewsScreenerChartsMapsGroupsPortfolioInsiderFuturesForexCryptoCalendarPricing
Theme 		Help

DSGN

Design Therapeutics Inc

Last Close
14.39
Aug 13 • 3:59 PM ET Dollar change-0.27 Percentage change(-1.84%)
Aftermarket Close
14.39
Aftermarket • 4:15 PM ET Dollar change0.00 Percentage change(0.00%)
Overview Compare Short Interest Financials Options Filings
Healthcare Biotechnology USA Small NASD
Peers: RYTM INCY KYMR BMRN CRNX VKTX KRYS AXSM MDGL NBIX
 | Held by: VTI IWM VXF IWO IBB FESM VTWO DFAS SCHA DFMC
Scroll to Statements
Index
RUT
Market Cap
900.55M
Enterprise Value
695.81M
Income
-70.80M
Sales
0.00M
Book/sh
3.23
Cash/sh
3.31
Dividend Est.
-
Dividend TTM
-
Dividend Ex-Date
-
Dividend Gr. 3/5Y
- -
Payout
-
Employees
124
IPO
Mar 26, 2021
P/E
-
Forward P/E
-
PEG
-
P/S
-
P/B
4.46
P/C
4.34
P/FCF
-
EV/EBITDA
-
EV/Sales
-
Quick Ratio
18.86
Current Ratio
18.86
Debt/Eq
0.01
LT Debt/Eq
0.01
Option/Short
Yes / Yes
EPS (ttm)
-1.18
EPS next Y
-1.56
EPS next Q
-0.34
EPS this Y
-8.78%
EPS next Y
-17.44%
EPS next 5Y
-17.03%
EPS past 3/5Y
-2.32% -52.23%
Sales past 3/5Y
- -
EPS Y/Y TTM
-5.51%
Sales Y/Y TTM
-
EPS Q/Q
3.87%
Sales Q/Q
-
Earnings
Aug 03 BMO
EPS/Sales Surpr.
7.06% -
Insider Own
39.71%
Insider Trans
0.00%
Inst Own
50.43%
Inst Trans
5.33%
ROA
-32.33%
ROE
-34.13%
ROIC
-34.72%
Gross Margin
-
Oper. Margin
-
Profit Margin
-
SMA20
11.75%
SMA50
11.56%
SMA200
31.08%
Trades
Shs Outstand
62.58M
Shs Float
37.73M
Short Float
15.78%
Short Ratio
6.46
Short Interest
5.95M
52W High
17.25 -16.58%
52W Low
4.68 207.48%
Volatility
3.81% 5.90%
ATR (14)
0.74
RSI (14)
62.61
Beta
1.67
Rel Volume
0.44
Avg Volume
921.37K
Volume
406,836
Perf Week
4.50%
Perf Month
6.43%
Perf Quarter
-7.87%
Perf Half Y
38.90%
Perf YTD
53.41%
Perf Year
165.50%
Perf 3Y
87.37%
Perf 5Y
-12.84%
Perf 10Y
-
Recom
1.00
Target Price
21.00
Prev Close
14.66
Price
14.39
Change %
-1.84%
Date Action Analyst Rating Change Price Target Change
May-12-26Initiated Cantor Fitzgerald Overweight
Mar-16-26Initiated Jefferies Buy $15
Jan-07-26Initiated Oppenheimer Outperform $18
Dec-03-25Upgrade Leerink Partners Market Perform → Outperform $14
Dec-03-25Initiated Craig Hallum Buy $15
Nov-20-25Upgrade RBC Capital Mkts Sector Perform → Outperform $13
May-07-24Upgrade Piper Sandler Neutral → Overweight $6 → $12
Nov-14-23Downgrade Piper Sandler Overweight → Neutral $42 → $6
Aug-15-23Downgrade Wedbush Outperform → Neutral $19 → $6
Aug-15-23Downgrade SVB Securities Outperform → Market Perform $6
Show Previous Ratings
Aug-03-26 08:00AM
Design Therapeutics Provides RESTORE-FA Clinical Development Update and Reports Second Quarter 2026 Financial Results
(GlobeNewswire)
Jun-30-26 08:00AM
Design Therapeutics Announces Initiation of Patient Dosing in Phase 1 Multiple Ascending Dose Trial of DT-818 for Myotonic Dystrophy Type-1
(GlobeNewswire)
May-28-26 08:00AM
Design Therapeutics to Participate in 2026 Jefferies Global Healthcare Conference
(GlobeNewswire)
May-18-26 11:02AM
This Biotech Leader Ran Up As Much As 18% - And Then Lost It All
(Investor's Business Daily) -25.54%
10:02AM
Design Therapeutics Shares Jump on Encouraging Friedreich Ataxia Trial Results (DSGN)
(InvestorsHub)
07:00AM Loading…
07:00AM
Design Therapeutics Announces Four-Week IV Data from the RESTORE-FA Trial of DT-216P2 Demonstrating Clinical Improvements and Comprehensive Biomarker Activity in Friedreich Ataxia
(GlobeNewswire)
May-17-26 04:00PM
Design Therapeutics to Host Investor Webcast to Review Data from RESTORE-FA Trial of DT-216P2 for Friedreich's Ataxia on Monday, May 18, 2026
(GlobeNewswire)
Apr-29-26 07:00PM
Design Therapeutics Inc (DSGN) Q1 2026 Earnings Call Highlights: Promising Progress in ...
(GuruFocus.com) +23.26% -13.87%
Apr-28-26 04:01PM
Design Therapeutics Announces First Quarter 2026 Financial Results and Recent Business Updates
(GlobeNewswire)
Mar-09-26 04:01PM
Design Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Recent Business Updates
(GlobeNewswire)
Feb-26-26 05:53AM
Design Therapeutics Highlights GeneTAC Pipeline, FA Data Timeline and DM1 Dosing Plans at Oppenheimer Conference
(MarketBeat)
Feb-18-26 08:00AM
Design Therapeutics to Participate in Upcoming Investor Conferences
(GlobeNewswire)
Nov-26-25 08:00AM
Design Therapeutics to Participate in Upcoming Investor Conferences
(GlobeNewswire)
Nov-20-25 09:21AM
Here Are Thursdays Top Wall Street Analyst Research Calls: AON, Apollo Global, Bullish, Jack Henry, Marsh & McClennan, Nasdaq, NVIDIA, and More
(24/7 Wall St.) +7.22%
Nov-05-25 04:01PM
Design Therapeutics Announces Plans to Initiate Patient Dosing of DT-818 in Myotonic Dystrophy Type-1 (DM1) in the First Half of 2026 and Reports Third Quarter 2025 Financial Results
(GlobeNewswire)
04:01PM Loading…
Sep-10-25 04:01PM
Design Therapeutics Appoints Justin Gover to Board of Directors
(GlobeNewswire) -7.68%
Aug-27-25 08:00AM
Design Therapeutics to Participate in the 2025 Cantor Global Healthcare Conference
(GlobeNewswire)
Aug-07-25 04:01PM
Design Therapeutics Highlights Progress Across Lead GeneTAC Programs and Reports Second Quarter 2025 Financial Results
(GlobeNewswire) -8.74% +7.81%
Jun-04-25 07:00AM
Design Therapeutics Announces Start of Friedreich Ataxia Patient Dosing Ex-U.S. in its RESTORE-FA Phase 1/2 Multiple-Ascending Dose Trial of DT-216P2
(GlobeNewswire)
May-28-25 08:00AM
Design Therapeutics to Participate in 2025 Jefferies Global Healthcare Conference
(GlobeNewswire)
May-13-25 08:00AM
Design Therapeutics to Participate in 2025 RBC Capital Markets Healthcare Conference
(GlobeNewswire)
May-07-25 04:01PM
Design Therapeutics Highlights Momentum Across Lead GeneTAC Programs and Reports First Quarter 2025 Financial Results
(GlobeNewswire) -8.26% +5.71%
May-02-25 07:58AM
Design Therapeutics reports positive outcomes from trial of DT-168 eye drops
(Clinical Trials Arena)
May-01-25 08:00AM
Design Therapeutics Announces Favorable Phase 1 Data for DT-168 Supporting Advancement into Phase 2 Biomarker Trial for Patients with Fuchs Endothelial Corneal Dystrophy
(GlobeNewswire)
Apr-21-25 04:01PM
Design Therapeutics to Present Phase 1 Data for Fuchs Endothelial Corneal Dystrophy Program at Eyecelerator @ Park City 2025
(GlobeNewswire) +10.31%
Apr-17-25 08:00AM
Design Therapeutics Appoints Veteran Industry Executive Chris Storgard, M.D., as Chief Medical Officer
(GlobeNewswire)
07:00AM
Bright Peak Therapeutics Appoints John Schmid to its Board of Directors
(GlobeNewswire)
Mar-12-25 12:00PM
Design Therapeutics (DSGN) Upgraded to Buy: Here's Why
(Zacks) -6.94%
Mar-10-25 07:07AM
Design Therapeutics Highlights Progress Across Lead GeneTAC Programs and Reports Fourth Quarter and Full Year 2024 Financial Results
(GlobeNewswire)
Mar-03-25 08:00AM
Design Therapeutics to Participate in Leerink's Global Healthcare Conference
(GlobeNewswire) -7.00%
08:00AM Loading…
Nov-13-24 08:00AM
Design Therapeutics to Participate in Multiple Upcoming Investor Conferences
(GlobeNewswire) +8.54%
Nov-07-24 04:01PM
Design Therapeutics Announces Third Quarter 2024 Financial Results and Reviews Near-term Milestones for GeneTACTM Portfolio
(GlobeNewswire)
Sep-10-24 08:00AM
Design Therapeutics to Participate in the 2024 Cantor Global Healthcare Conference
(GlobeNewswire) +15.69%
Aug-21-24 09:55AM
Wall Street Analysts Think Design Therapeutics (DSGN) Could Surge 39.72%: Read This Before Placing a Bet
(Zacks)
Aug-05-24 08:00AM
Design Therapeutics Announces Second Quarter 2024 Financial Results and Reviews Near-term Milestones for GeneTAC Portfolio
(GlobeNewswire)
May-22-24 08:50PM
The 100%+ Club: Piper Sandler's 3 Top Picks for Triple-Digit Gains
(InvestorPlace)
May-10-24 03:36PM
Design Therapeutics Inc (DSGN) Q1 2024 Earnings: A Detailed Financial and Strategic Review
(GuruFocus.com)
May-08-24 11:55PM
DSGN Stock Earnings: Design Therapeutics Beats EPS for Q1 2024
(InvestorPlace)
04:05PM
Design Therapeutics Announces First Quarter 2024 Financial Results and Highlights Upcoming Program Milestones
(GlobeNewswire)
May-07-24 07:12AM
--Piper Sandler Upgrades Design Therapeutics to Overweight From Neutral
(MT Newswires) +28.49%
06:30AM
Design Therapeutics to Participate in the 2024 RBC Capital Markets Global Healthcare Conference
(GlobeNewswire)
Mar-20-24 10:31AM
Design Therapeutics, Inc. (NASDAQ:DSGN) Q4 2023 Earnings Call Transcript
(Insider Monkey) +11.97%
06:58AM
Q4 2023 Design Therapeutics Inc Earnings Call
(Thomson Reuters StreetEvents)
Mar-19-24 08:53PM
DSGN Stock Earnings: Design Therapeutics Beats EPS for Q4 2023
(InvestorPlace)
05:33PM
Design Therapeutics Inc (DSGN) Reports Full Year 2023 Financial Results and Pipeline Progress
(GuruFocus.com)
04:01PM
Design Therapeutics Outlines Progress Across GeneTAC Platform and Announces Fourth Quarter and Full Year 2023 Financial Results
(GlobeNewswire)
Mar-12-24 06:30AM
Design Therapeutics to Webcast Fourth Quarter and Full Year 2023 Financial Results and Comprehensive Portfolio Update
(GlobeNewswire)
Dec-18-23 12:00PM
Design Therapeutics, Inc. (DSGN) Upgraded to Buy: Here's What You Should Know
(Zacks)
Nov-14-23 07:28PM
Design Therapeutics Inc (DSGN) Reports Q3 2023 Financials, Plans Strategic Update
(GuruFocus.com) +11.71%
Nov-13-23 04:05PM
Design Therapeutics Reports Third Quarter 2023 Financial Results and Plans for a Comprehensive Portfolio Update in Early 2024
(GlobeNewswire)
Aug-15-23 03:02PM
Why Shares of Design Therapeutics Are Plummeting on Tuesday
(Motley Fool) -70.46%
09:59AM
Redfin upgraded, CSSE downgraded: Wall Street's top analyst calls
(The Fly)
02:34AM
4 big analyst cuts: Urban Outfitters has 'limited' EPS upside, per Citi
(Investing.com)
Aug-14-23 04:05PM
Design Therapeutics Provides Pipeline Update and Reports Second Quarter 2023 Financial Results
(GlobeNewswire)
04:01PM
Design Therapeutics Reports Initial Results from Phase 1 Multiple-Ascending Dose Study of DT-216 for the Treatment of Friedrich Ataxia
(GlobeNewswire)
Jun-18-23 08:03AM
Pleasing Signs As A Number Of Insiders Buy Design Therapeutics Stock \
(Simply Wall St.)
May-31-23 06:30AM
Design Therapeutics to Present at the 2023 Jefferies Healthcare Conference
(GlobeNewswire) -6.01%
May-09-23 04:05PM
Design Therapeutics Provides Pipeline Updates and Reports First Quarter 2023 Financial Results
(GlobeNewswire) -11.66%
May-08-23 06:05AM
We're Hopeful That Design Therapeutics (NASDAQ:DSGN) Will Use Its Cash Wisely
(Simply Wall St.)
Apr-24-23 06:30AM
Design Therapeutics to Present Preclinical Data on its GeneTAC Small Molecule, DT-168, for the Treatment of Fuchs Endothelial Corneal Dystrophy at ARVO 2023
(GlobeNewswire)
Apr-11-23 09:55AM
Why Design Therapeutics (DSGN) Stock Is Going Nowhere But Down
(InvestorPlace)
Apr-04-23 02:47PM
Down More Than 60%: Analysts Say Buy These 3 Beaten-Down Stocks Before They Rebound
(TipRanks) -7.32%
Mar-14-23 04:05PM
Design Therapeutics Highlights Pipeline Progress and Reports Fourth Quarter and Full Year 2022 Financial Results
(GlobeNewswire)
Mar-09-23 06:33AM
Daily Vickers Top Insider Picks for 03/09/2023
(Argus Research)
Feb-08-23 06:30AM
Design Therapeutics to Participate in the SVB Securities Virtual Global Biopharma Conference
(GlobeNewswire) -8.79%
Dec-21-22 06:46AM
Daily Vickers Top Buyers & Sellers for 12/21/2022
(Argus Research) +5.33%
Dec-14-22 05:15AM
Independent Director Rodney Lappe Just Bought 15% More Shares In Design Therapeutics, Inc. (NASDAQ:DSGN)
(Simply Wall St.)
Dec-07-22 04:01PM
Design Therapeutics Reports Positive Data from Single-Ascending Dose Trial of DT-216 for the Treatment of Friedreich Ataxia and Portfolio Progress
(GlobeNewswire) -6.00% -33.33%
Nov-28-22 10:37AM
Companies Like Design Therapeutics (NASDAQ:DSGN) Are In A Position To Invest In Growth
(Simply Wall St.)
Nov-03-22 04:05PM
Design Therapeutics Highlights Pipeline Progress and Upcoming Milestones and Reports Third Quarter 2022 Financial Results
(GlobeNewswire)
Oct-17-22 04:05PM
Design Therapeutics to Present Preclinical Data Highlighting the Potential of its GeneTAC Small Molecule, DT-216, for the Treatment of Friedreich Ataxia at ICAR 2022
(GlobeNewswire)
Sep-22-22 06:30AM
Design Therapeutics to Present at the 2022 Jefferies Cell and Genetic Medicine Summit
(GlobeNewswire)
Aug-08-22 04:05PM
Design Therapeutics Highlights Upcoming Milestones and Reports Second Quarter 2022 Financial Results
(GlobeNewswire)
Aug-03-22 06:30AM
Design Therapeutics to Participate in the 2022 Wedbush PacGrow Virtual Healthcare Conference
(GlobeNewswire) +6.33%
Jun-21-22 09:57AM
Companies Like Design Therapeutics (NASDAQ:DSGN) Are In A Position To Invest In Growth
(Simply Wall St.) +6.24%
Jun-01-22 06:30AM
Design Therapeutics to Present at the 2022 Jefferies Healthcare Conference
(GlobeNewswire)
May-09-22 04:05PM
Design Therapeutics Highlights Clinical and Research Progress and Reports First Quarter 2022 Financial Results
(GlobeNewswire)
Mar-30-22 06:30AM
Design Therapeutics Completes Dosing in First Patient Cohort of Phase 1 Trial of DT-216 GeneTAC Molecule for the Treatment of Friedreich Ataxia
(GlobeNewswire)
Mar-23-22 02:53PM
Design Therapeutics, Inc. (NASDAQ:DSGN) insiders placed bullish bets worth US$1.2m in the last 12 months
(Simply Wall St.)
Mar-10-22 04:02PM
Design Therapeutics Reports Pipeline and Business Progress and Fourth Quarter and Full Year 2021 Financial Results
(GlobeNewswire)
Mar-09-22 06:30AM
Design Therapeutics Announces Preclinical Data Highlighting Novel GeneTAC Therapy for the Treatment of Fuchs Endothelial Corneal Dystrophy to be Presented at ARVO 2022
(GlobeNewswire) +9.41%
Feb-28-22 04:05PM
Design Therapeutics Announces FDA Clearance of Investigational New Drug Application for First GeneTAC Molecule for Friedreich Ataxia
(GlobeNewswire)
Feb-10-22 06:30AM
Design Therapeutics to Present at the SVB Leerink 11th Annual Global Healthcare Conference
(GlobeNewswire) +7.02%
Feb-01-22 04:05PM
Design Therapeutics Appoints Drug Development Expert, Jae Kim, M.D., as Chief Medical Officer
(GlobeNewswire)
Jan-19-22 12:51PM
Design Therapeutics Shares Fall As Goldman Sachs Initiates With Sell Rating
(Benzinga) -5.86%
Dec-23-21 05:00AM
Design Therapeutics (NASDAQ:DSGN) Is In A Good Position To Deliver On Growth Plans
(Simply Wall St.) +5.09%
Nov-09-21 04:05PM
Design Therapeutics Reports Pipeline Progress and Third Quarter 2021 Results
(GlobeNewswire)
Sep-24-21 07:55AM
Design Therapeutics, Inc. (NASDAQ:DSGN) insiders placed bullish bets worth US$1.2m in the last 12 months
(Simply Wall St.)
Sep-08-21 06:30AM
Design Therapeutics Announces Positive Preclinical Data Highlighting Disease-Modifying Potential of its Novel DM1 GeneTACs as a Treatment for Myotonic Dystrophy Type-1
(GlobeNewswire)
Sep-03-21 07:33AM
4 Stocks Insiders Are Buying
(Benzinga)
Aug-09-21 04:05PM
Design Therapeutics Reports GeneTAC Portfolio Progress and Second Quarter 2021 Results
(GlobeNewswire) +6.19%
Jun-26-21 04:30AM
We're Hopeful That Design Therapeutics (NASDAQ:DSGN) Will Use Its Cash Wisely
(Simply Wall St.)
Jun-07-21 04:10PM
Design Therapeutics to Participate in Goldman Sachs 42nd Annual Global Healthcare Conference
(GlobeNewswire)
04:05PM
Design Therapeutics Expands Board of Directors with Key Appointments
(GlobeNewswire)
May-10-21 04:05PM
Design Therapeutics Announces Business Highlights and Reports First Quarter 2021 Financial Results
(GlobeNewswire) -6.82%
Mar-30-21 04:05PM
Design Therapeutics Announces Closing of Initial Public Offering and Full Exercise of Underwriters Option to Purchase Additional Shares
(GlobeNewswire) -13.20%
Mar-25-21 11:56PM
Design Therapeutics Announces Pricing of Initial Public Offering
(GlobeNewswire)
Design Therapeutics, Inc. operates as a biotechnology company that develops therapies for serious degenerative disorders. It is created to design, develop and commercialize a novel class of small molecule therapeutic candidates (GeneTACs) designed to directly address the underlying basis of genetic disease. The company was founded by Pratik Shah and Aseem Z. Ansari on December 18, 2017 and is headquartered in Carlsbad, CA.
Co-FounderMr. Pratik Shah Ph.D.
Chief Operating OfficerDr. Sean Jeffries Ph.D.
Chief Medical OfficerDr. Chris M. Storgard M.D.
Co-Founder & Scientific AdvisorDr. Aseem Z. Ansari Ph.D.
Chief Accounting OfficerMs. Julie D. Burgess CPA
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Logos Global Master Fund LPDirectorNov 18 '25Proposed Sale7.43120,000891,600Nov 18 04:28 PM
Logos Global Master Fund LPDirectorNov 14 '25Proposed Sale7.06620,0004,377,200Nov 14 04:18 PM
Logos Global Master Fund LPDirectorNov 07 '25Proposed Sale6.87415,0002,851,050Nov 07 05:24 PM
open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR
Affiliate • Advertise • Careers • Contact • Blog • Help • Privacy • Follow us on X • Do Not Sell My Personal Information
Quotes delayed 1 minute for NASDAQ, NYSE and AMEX.
Copyright © 2007-2026 Finviz.com. All Rights Reserved. Export All Screener Data (CSV)